AUTOLUS THERAPEUTICS PLC
Autolus Therapeutics plc (AUTL) is a clinical‑stage biotechnology company developing engineered T‑cell (CAR‑T) therapies for cancer. With a market capitalisation of roughly $433.8m, it is a small‑cap, research‑intensive group whose value depends heavily on trial results, regulatory decisions and potential partnerships. Investors should know that Autolus has no broad commercial revenue stream today and that clinical milestones and safety data are binary events that can drive significant share‑price moves. The company’s outlook hinges on successful patient outcomes, cost controls and access to funding; this makes the stock suitable primarily for investors comfortable with high volatility, long time horizons and the possibility of capital loss. This summary is for educational purposes only and not personalised advice — consider diversification and professional guidance when assessing suitability.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AUTOLUS stock, anticipating significant growth with a target price of $9.30.
Financial Health
Autolus Therapeutics is generating modest revenue, indicating a stable but not exceptional financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Major trial readouts and regulatory decisions can change valuation quickly, offering potential upside but bringing binary risk.
Targeted cancer focus
Programmes aim at specific haematological cancers and possibly solid tumours; scientific progress matters more than short‑term market moves.
Cutting‑edge engineering
Autolus uses advanced T‑cell engineering techniques, which could deliver breakthroughs, though development is costly and uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
